NASDAQ:QLGN

Qualigen Therapeutics (QLGN) News Today

$0.94

+0.02 (+2.18%)

(As of 06/1/2023 ET)

Compare

Today's Range: $0.92
▼
$0.96
50-Day Range: $0.87
▼
$1.09
52-Week Range: $0.83
▼
$6.50

Volume: 2,002 shs
Average Volume: 23,486 shs
Market Capitalization: $4.74 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Get Qualigen Therapeutics News Delivered to You Automatically

QLGN Media Mentions By Week

QLGN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

QLGN
News Sentiment
▼
1.00

0.47
▲
Average
Medical
News Sentiment

QLGN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

QLGN Articles
This Week
▼
0

1
▲
QLGN Articles
Average Week

Source

Source	Headline
	Qualigen Therapeutics GAAP EPS of -$0.78, revenue of $1.61M seekingalpha.com - May 18 at 9:54 AM
	Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Expected to Earn Q1 2023 Earnings of ($0.85) Per Share americanbankingnews.com - May 17 at 1:20 AM
	Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023 finance.yahoo.com - May 16 at 10:33 AM
	QLGN: IND for QN-302 to be Submitted in Mid-2023… finance.yahoo.com - May 12 at 2:06 PM
	Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update finance.yahoo.com - May 2 at 9:10 PM
	Qualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting finance.yahoo.com - May 2 at 10:31 AM
	Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing finance.yahoo.com - April 21 at 6:57 PM
	Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL finance.yahoo.com - April 18 at 10:43 AM
	Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL finance.yahoo.com - April 18 at 10:43 AM
	Short Interest in Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Grows By 48.8% americanbankingnews.com - April 18 at 6:38 AM
	Qualigen Therapeutics, Inc.: Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office finanznachrichten.de - March 21 at 2:06 PM
	Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office finance.yahoo.com - March 21 at 9:05 AM
	Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023 finance.yahoo.com - March 15 at 2:31 PM
	Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference finance.yahoo.com - March 9 at 9:02 AM
	Data on Potential Biomarker for Qualigen Therapeutics’ Lead Program QN-302 Published in Peer-Reviewed Journal Molecules finance.yahoo.com - March 8 at 9:34 AM
	Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders finance.yahoo.com - February 1 at 1:03 PM
	Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302 finance.yahoo.com - January 24 at 1:26 PM
	Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications finance.yahoo.com - January 23 at 3:34 PM
	Qualigen Therapeutics' QN-302 Receives FDA's Orphan Drug Designation marketwatch.com - January 10 at 9:48 AM
	Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer finance.yahoo.com - January 10 at 9:48 AM
	Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform finance.yahoo.com - January 5 at 10:40 AM
	Qualigen Therapeutics, Inc.: Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule finanznachrichten.de - December 13 at 7:09 AM
	Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule technews.tmcnet.com - December 12 at 8:46 AM
	Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors finance.yahoo.com - December 7 at 3:22 PM
	QLGN: Encouraging Preclinical Data Presented for QN-302 and RAS Inhibitor… finance.yahoo.com - December 1 at 7:30 PM
	Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split finance.yahoo.com - November 22 at 8:01 PM
	Qualigen Therapeutics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag finance.yahoo.com - November 17 at 6:56 AM
	Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update finance.yahoo.com - November 15 at 10:59 AM
	QLGN Qualigen Therapeutics, Inc. seekingalpha.com - October 21 at 10:31 PM
	Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute finance.yahoo.com - October 19 at 4:56 PM
	Qualigen Therapeutics to Present at LD Micro Main Event XV finance.yahoo.com - October 18 at 11:22 AM
	Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium finance.yahoo.com - October 6 at 1:37 PM
	Qualigen Therapeutics Presents Data on QN-302 at AACR's Pancreatic Cancer Meeting stockhouse.com - September 15 at 9:39 PM
	Qualigen Therapeutics Presents Data on QN-302 at AACR’s Pancreatic Cancer Meeting finance.yahoo.com - September 14 at 9:07 PM
	QLGN: FastPack Sales Up 28% YoY… finance.yahoo.com - August 25 at 5:23 PM
	Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board finance.yahoo.com - August 18 at 9:42 AM
	Qualigen Therapeutics, Inc. Tops Q2 EPS by 5c uk.investing.com - August 17 at 6:40 PM
	Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update finance.yahoo.com - August 16 at 12:38 PM
	Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model finance.yahoo.com - August 1 at 9:39 AM
	Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302 finance.yahoo.com - July 6 at 5:22 PM
	Qualigen Therapeutics announces secondary offering of 8.16M shares seekingalpha.com - June 17 at 7:11 PM
	Qualigen Therapeutics to Present at BIO International Convention finance.yahoo.com - June 14 at 12:27 PM
	Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials finance.yahoo.com - June 7 at 4:41 PM
	QLGN: Acquires Majority Stake in Israeli Diagnostics Technology Company NanoSynex… finance.yahoo.com - June 6 at 12:03 PM
	Qualigen stock rises on acquiring majority stake in Israeli diagnostics company NanoSynex seekingalpha.com - June 2 at 6:08 PM
	Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex finance.yahoo.com - June 2 at 9:42 AM
	Qualigen Therapeutics’ Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual Meeting finance.yahoo.com - May 26 at 11:18 AM
	Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference finance.yahoo.com - May 20 at 3:27 PM
	Qualigen Takes Stake In NanoSynex To Gain Access To Next-Gen Diagnostic Platform finance.yahoo.com - May 3 at 8:42 PM
	Qualigen to acquire majority stake in Israeli diagnostics company NanoSynex seekingalpha.com - May 3 at 10:41 AM

Get Qualigen Therapeutics News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:QLGN) was last updated on 6/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Qualigen Therapeutics (QLGN) News Today

QLGN Media Mentions By Week

QLGN Media Sentiment

QLGN News Coverage

Related Companies and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info